Mr. Ou Lei Qiang, CEO of Baiji Shenzhou, was elected to the board of directors of Bio

On June 4, Baiji announced today that Mr Ou Lei Qiang, co-founder, chairman and CEO of the company, was officially elected to the board of directors of the Biotechnology Industry Association (bio) and the board of directors of the health sector of bio The latter is in charge of policy and regulatory affairs and topics that have an important impact on the biotechnology industry "It's a great honor for me to be able to contribute to the unity of bio's global biotechnology colleagues on key industrial topics," Mr o'reiqiang said The mission of bio and the mission of Baiji Shenzhou complement each other The purpose of my founding is to attract passionate and mission oriented talents from China, the United States and all over the world to develop innovative drugs of the highest quality for patients " Mr o'reiqiang co founded Baiji Shenzhou in 2010 and developed it into a business stage biotechnology company with about 2400 employees in mainland China, the United States, Australia and Europe Baiji Shenzhou focuses on the development and commercialization of innovative molecular targeting and immune tumor drugs for cancer treatment Jim Greenwood, CEO and President of bio commented: "we welcome Mr o'reiqiang to the board of directors and believe that as an important new member, he can bring unique insights to bio on the topic of global medical popularization All of our board members are industry experts, helping bio actively promote public policy in the United States and around the world The goal of bio is to continue to promote breakthrough medical therapies, improve agricultural products and promote revolutionary biofuels " Bio is the world's largest biotechnology industry organization, representing biotechnology companies, academic research institutes, National Biotechnology centers and related organizations in more than 30 countries, including the United States Bio members play an active role in the research and development of innovative medical, agricultural, industrial and environmental biotechnology products About Baiji Shenzhou, a global, commercial stage, R & D-based biotechnology company, focusing on the research and development of molecular targeting and immunotherapy for tumor At present, Baiji Shenzhou has about 2400 employees in mainland China, the United States, Australia and Europe, and its research product line includes new oral small molecule and monoclonal antibody anti-cancer drugs At present, Baiji Shenzhou is also building a drug combination program for anti-cancer treatment, aiming to bring lasting and far-reaching impact on the life of cancer patients Under the authorization of Xinji company, Baiji Shenzhou sells Abraxane ® paclitaxel for injection (nano albumin particle binding type), refume ® (lenalidomide capsule) and vedasha ® (azacytidine for injection) in China [i] [i] Abraxane ®, rifeme ® and vitasa ® are registered trademarks of new base pharmaceutical company.